- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03202277
BeWell24: Smartphone-based Diabetes Prevention in the VA
May 8, 2020 updated by: Arizona State University
Type 2 diabetes (T2D) is a national epidemic and current lifestyle programs and medications are not effectively managing the crisis.
This project aims to test a novel smartphone-delivered intervention that simultaneously targets multiple health behaviors (i.e., sleep, sedentary behavior, physical activity,dietary intake) within clinical settings at a large Veteran Health Administration regional hospital.
If effective, this project has potential for large-scale implementation nationwide through the VA healthcare system and broad applicability for other populations at T2D risk as well as other disorders.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Type 2 diabetes (T2D) affects 26 million Americans and "prediabetes" affects 86 million more.
If this epidemic is not addressed immediately, 23% of Americans will have T2D by 2030.
Current lifestyle programs to prevent diabetes are complex to deliver, costly, and have limited scalability.
Medications do not clearly modify the disease process and have a number of side effects.
New approaches are needed that can address this epidemic on a population scale.
mHealth technologies (e.g., smartphones) are deeply integrated into our lives and can target the daily lifestyle behaviors that underpin the T2D epidemic.
The Veterans Health Administration (VHA) is an ideal setting to test mHealth approaches because they are at the forefront of harnessing smartphone technologies to deliver care with the advent of the "VA App Store."
As the nation's largest integrated healthcare system, VHA has a central dissemination infrastructure to deliver smartphone interventions to over 5.5 million Veterans.
BeWell24, an adaptive and multicomponent smartphone "app" was developed based on the unique needs and desires of US Veterans and VHA clinical teams.
BeWell24 targets behaviors across the 24 hours - sleep, sedentary behavior, and more active behaviors - and preliminary data suggest reductions in fasting glucose among prediabetics of 12.3% in just 8 weeks of use.
A dietary component will be added to the app to further enhance the potency of the intervention.
The objective now is to test whether the delivery and integration of this app into routine clinical care settings can improve glycemic control over 9 months.
A randomized controlled trial of 120 prediabetic Veterans is proposed.
The first aim is to test whether BeWell24 significantly improves glycemic control (reduce fasting glucose and HbA1c) over 9 months relative to usual care.
Objectively-measured changes is targeted behaviors (sleep, sedentary behavior, physical activity, and dietary intake) and other key cardiometabolic biomarkers (weight/body fat, blood pressure, lipids, insulin, and hs-CRP) will also be explored.
The second and third aims are to assess factors impacting scalability of BeWell24 from patient and provider perspectives to optimize opportunities for large-scale dissemination if efficacious.
Program reach/retention, app usage, treatment acceptability, program costs, and clinical integration factors will be studied.
Unique features of this proposal are the rigorous cluster-randomized design; testing in a highly integrated, nationwide, clinical setting; and use of a highly sophisticated smartphone platform uniquely designed for the population and targets multiple health behaviors impacting T2D risk.
The long-term goal is to establish an effective diabetes prevention program among Veterans that can be used to complement and enhance existing clinical support.
If effective, this approach could be rapidly scaled to Veterans nationwide and could have broad applicability for other populations at disparate T2D risk as well as other disorders.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85012
- Phoenix VA Healthcare System
-
Tempe, Arizona, United States, 85281
- Arizona State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Veterans ages 18 and older
- Regularly use an appropriate Apple (iOS6 or higher) or Android (2.3 or higher) smartphone or tablet device
- Risk for "prediabetes" based upon clinician judgment - clinicians may rely on laboratory data review in the prior 12 months including: (a) HbA1c 5.7-6.4%; and (b) glucose, HDL-cholesterol, triglycerides, and weight
Exclusion Criteria:
- long distance or insufficient transportation to the Veterans hospital to make participation in quarterly visits difficult;
- severe personal, health, cognitive or psychological conditions that prevent participation or severely limit lifestyle changes
- limited physical mobility, untreated sleep disorder, or other underlying disorder that requires treatment or would make lifestyle change contraindicated
- current participation in other diet, weight loss, or lifestyle programs
- recent or imminent changes in medications that would substantially alter glucose metabolism (e.g., steroids, anti-depressive medications associated with weight gain)
- recent weight gain or loss of more than 10 kg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: BeWell24 smartphone app
Smartphone app, linked with commercial activity monitor, to support lifestyle changes in physical activity, sleep, sedentary behavior, and dietary intake.
|
This app delivers an evidence-based suite of lifestyle interventions targeting behavior change in sleep, sedentary behavior, physical activity, and dietary intake.
The app connects with a commercially available activity monitor to provide real-time feedback on behaviors over time.
|
|
Active Comparator: Health education smartphone app
Smartphone app with basic health education content, designed to control for non-specific treatment effects and match for smartphone app novelty.
|
This app delivers basic health education and hygiene content related to sleep, sedentary behavior, physical activity, and dietary intake.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HbA1c
Time Frame: 9 months
|
Circulating levels of Hemoglobin A1c
|
9 months
|
|
Fasting glucose
Time Frame: 9 months
|
Fasting levels of glucose
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sleep duration (minutes/night) measured by wrist actigraphy
Time Frame: 9 months
|
Sleep duration (measured by wrist actigraphy)
|
9 months
|
|
Sedentary behavior (minutes/day) measured by wrist actigraphy
Time Frame: 9 months
|
Measure of sedentary time (measured by wrist actigraphy)
|
9 months
|
|
Moderate-vigorous physical activity (minutes/day) measured by wrist actigraphy
Time Frame: 9 months
|
Measure of moderate-vigorous physical activity (measured by wrist actigraphy)
|
9 months
|
|
Dietary quality measured by the NCI dietary factor screener
Time Frame: 9 months
|
Self-reported dietary quality
|
9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 17, 2017
Primary Completion (Actual)
December 14, 2019
Study Completion (Actual)
December 14, 2019
Study Registration Dates
First Submitted
June 23, 2017
First Submitted That Met QC Criteria
June 26, 2017
First Posted (Actual)
June 28, 2017
Study Record Updates
Last Update Posted (Actual)
May 11, 2020
Last Update Submitted That Met QC Criteria
May 8, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R18DK109516 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
Medical University of GrazCompletedType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes, Insulin RequiringAustria
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Canterbury Christ Church UniversityBarts & The London NHS Trust; Betsi Cadwaladr University Health BoardRecruitingType 1 Diabetes Mellitus | Type 2 Diabetes Mellitus (T2DM)United Kingdom
Clinical Trials on BeWell24 smartphone app
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnMalignant Solid Neoplasm | Sarcoma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Central Nervous System NeoplasmUnited States
-
Population Health Research InstituteUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); Childhood Obesity Foundation and other collaboratorsActive, not recruiting
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center; American...Active, not recruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
University of WashingtonCompletedDepression | AnxietyUnited States
-
NYU Langone HealthNational Institutes of Health (NIH)Recruiting
-
University GhentCompletedSuicidal Ideation | Suicidal Behavior | Coping BehaviorBelgium
-
Hartford HospitalNational Institute of Mental Health (NIMH); Oui Therapeutics, Inc.CompletedSuicidal Ideation | Suicide, AttemptedUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteNational Institute on Drug Abuse (NIDA)Recruiting
-
World BankDepartment for International Development, United Kingdom; Wits Reproductive... and other collaboratorsCompletedHIV Infections | Antiretroviral Therapy | Patient Compliance | Viral Load | Cell PhoneSouth Africa
-
Universitätsklinikum Hamburg-EppendorfUnknownMultiple Sclerosis, Chronic Progressive